COVID-19 vaccines

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

Tuesday, May 11, 2021 - 7:30am

\xe2\x80\x9cWe are grateful to all of our clinical trial volunteers and their families, whose courage helped make this milestone possible.

Key Points: 
  • \xe2\x80\x9cWe are grateful to all of our clinical trial volunteers and their families, whose courage helped make this milestone possible.
  • Topline results from this trial, announced on March 31, 2021, showed a vaccine efficacy of 100% in participants with or without prior SARS-CoV-2 infection and robust antibody responses.
  • In the trial, the vaccine was also generally well tolerated.
  • \xe2\x80\x9cOur work is not yet complete, as we continue our research into the use of our vaccine in pediatric populations.

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

Tuesday, May 11, 2021 - 2:02am

This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.\nThis press release features multimedia.

Key Points: 
  • This is the first COVID-19 vaccine authorized in the U.S. for use in this age group.\nThis press release features multimedia.
  • \xe2\x80\x9cWe are grateful to all of our clinical trial volunteers and their families, whose courage helped make this milestone possible.
  • Topline results from this trial, announced on March 31, 2021, showed a vaccine efficacy of 100% in participants with or without prior SARS-CoV-2 infection and robust antibody responses.
  • \xe2\x80\x9cOur work is not yet complete, as we continue our research into the use of our vaccine in pediatric populations.

Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic

Monday, May 10, 2021 - 10:25pm

"Today\'s action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic.

Key Points: 
  • "Today\'s action allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic.
  • Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations.
  • The issuance of an EUA is not an FDA approval (licensure) of a vaccine.
  • The side effects in adolescents were consistent with those reported in clinical trial participants 16 years of age and older.

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

Monday, May 10, 2021 - 9:01pm

We believe that ARCT-021, as a single shot lyophilized self-amplifying mRNA vaccine, if approved, may represent a preferred vaccine option.

Key Points: 
  • We believe that ARCT-021, as a single shot lyophilized self-amplifying mRNA vaccine, if approved, may represent a preferred vaccine option.
  • We are very pleased with the recent successes in our mRNA drug product manufacturing efforts, and in the expansion of our global safety database \xe2\x80\x93 and the positive readthrough this provides to the Company\xe2\x80\x99s pipeline of mRNA therapeutics.
  • The primary driver of the sequential increase was driven by higher clinical and manufacturing cost of $17.2 million for our ARCT-021 program.
  • Based on our current plans, the Company\xe2\x80\x99s cash position is expected to be sufficient to support operations for more than two years.\nMonday, May 10th @ 4:30 p.m. ET\n'

Global Cancer Vaccine Partnering Deal Terms and Agreements Directory 2010-2021 - ResearchAndMarkets.com

Monday, May 10, 2021 - 4:30pm

b'The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 320 Cancer Vaccine deals.\nThis report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.\nThe report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.\nThe report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.\nThe middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.\nOne of the key highlights of the report is that over 320 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference.

Key Points: 
  • b'The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Cancer Vaccine Partnering Terms and Agreements 2010-2021 report provides comprehensive access to available deals and contract documents for over 320 Cancer Vaccine deals.\nThis report provides details of the latest Cancer Vaccine agreements announced in the life sciences since 2010.\nThe report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.\nThe report presents financial deal term values for Cancer Vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.\nThe middle section of the report explores the leading dealmakers in the Cancer Vaccine partnering field; both the leading deal values and most active Cancer Vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.\nOne of the key highlights of the report is that over 320 online deal records of actual Cancer Vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference.
  • Each deal record in the report links via Weblink to an online version of the deal.\nIn addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
  • Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.\nThe report also includes numerous tables and figures that illustrate the trends and activities in Cancer Vaccine partnering and dealmaking since 2010.\nIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Vaccine technologies and products.\nGlobal Cancer Vaccine Partnering Terms and Agreements 2010-2021 provides the reader with the following key benefits:\nInsight into terms included in a Cancer Vaccine partnering agreement, with real world examples\nAvailable deals are listed by:\n'

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Monday, May 10, 2021 - 12:00pm

In this study, a single intranasal dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.

Key Points: 
  • In this study, a single intranasal dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.
  • AdCOVID is a novel, single-dose intranasal vaccine candidate for COVID-19.\n\xe2\x80\x9cThese latest data are very exciting, as they confirm and expand upon the numerous potential advantages of our differentiated intranasal vaccine approach,\xe2\x80\x9d said Scot Roberts, Ph.D., Chief Scientific Officer at Altimmune.
  • \xe2\x80\x9cIn the current study, we found a heavy burden of infectious SARS-CoV-2 virus in the lungs of non-vaccinated mice following challenge with the virus.
  • Roberts continued, \xe2\x80\x9cThese data suggest that a single intranasal vaccination with AdCOVID may provide sterilizing immunity that neutralizes infectious virus, which is believed to be the best way to block viral transmission.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed

Saturday, May 8, 2021 - 4:41pm

31, 2021, media reports revealed the company mixed up ingredients for J&J\xe2\x80\x99s and AstraZeneca\xe2\x80\x99s vaccines, contaminating up to 15 million J&J vaccine doses.\nThis news caused Emergent shares to decline.

Key Points: 
  • 31, 2021, media reports revealed the company mixed up ingredients for J&J\xe2\x80\x99s and AstraZeneca\xe2\x80\x99s vaccines, contaminating up to 15 million J&J vaccine doses.\nThis news caused Emergent shares to decline.
  • Notably, shortly before this disclosure, Emergent\xe2\x80\x99s CEO sold $10 million of his shares.\nOn Apr.
  • For more information, call Reed Kathrein at 844-916-0895 or email EBS@hbsslaw.com .\nHagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.
  • For the latest news visit our newsroom or follow us on Twitter at @classactionlaw .\n'

Publix Accepts Walk-in Customers for COVID‑19 Vaccinations in All Seven of Its States

Friday, May 7, 2021 - 7:00pm

Customers who receive the Moderna vaccine will be provided with an appointment to receive their second dose.

Key Points: 
  • Customers who receive the Moderna vaccine will be provided with an appointment to receive their second dose.
  • The Johnson & Johnson vaccine requires only one dose.\nAppointments are encouraged for the most efficient vaccination experience and to ensure the preferred vaccine is available.
  • Appointments can be made through the online reservation system at publix.com/covidvaccine , and same day appointments may be available.
  • Appointments cannot be made by calling Publix or the Publix Pharmacy.\nVaccinations are provided to eligible individuals, while supplies last, and at no cost to the individual.

Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update

Friday, May 7, 2021 - 1:00pm

Importantly, data from multiple trials at Ocuphire have been published in several peer-reviewed journals and presented at multiple ophthalmic and healthcare banking conferences, further establishing our presence within the industry.

Key Points: 
  • Importantly, data from multiple trials at Ocuphire have been published in several peer-reviewed journals and presented at multiple ophthalmic and healthcare banking conferences, further establishing our presence within the industry.
  • Nyxol is also currently in Phase 2 for presbyopia, with top-line results expected Q2 2021, and in Phase 3 clinical development for NVD with top-line results expected Q3 2021.
  • APX3330 is actively recruiting in a Phase 2 trial in DR/DME, with results expected in early 2022.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Ocugen Provides Business Update and First Quarter 2021 Financial Results

Friday, May 7, 2021 - 12:30pm

COVAXIN has additionally demonstrated a remarkable safety profile with several million doses administered to date in India.

Key Points: 
  • COVAXIN has additionally demonstrated a remarkable safety profile with several million doses administered to date in India.
  • Based on broad immunogenicity, Ocugen believes that COVAXIN has the potential to be effective against other emerging variants.
  • To access a live audio webcast of the call on the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the Ocugen website, please click here .
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.